ASKA Pharmaceutical Holdings (4886) · InitiativeAchieved
Approval of an Additional Endometriosis Indication for Relumina
First written in FY2022-Q3. 1 of 2 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2022.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Approval of an Additional Endometriosis Indication for ReluminaA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022AchievedAnnual report
「レルミナ錠40mg（レルゴリクス）については、「子宮筋腫に基づく諸症状（過多月経、下腹痛、腰痛、貧血）の改善」に加え、2021年12月に「子宮内膜症に基づく疼痛の改善」を効能効果として承認を取得しました。」
レルミナ錠40mgの子宮内膜症適応追加承認の取得完了を年次報告で確認している。 - FY2022-Q3AdvancedAnnual report
「For Relumina Tablets 40 mg (relugolix), which was being developed for an additional indication for endometriosis, approval was obtained in December 2021 for the indication of improving pain associated with endometriosis, in addition to improving symptoms associated with uterine fibroids, including heavy menstrual bleeding, lower abdominal pain, back pain and anemia.」
Approval for the additional endometriosis indication for Relumina Tablets 40 mg was obtained in December 2021.